270 related articles for article (PubMed ID: 24606220)
1. Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV.
Boyd A; Maylin S; Gozlan J; Delaugerre C; Simon F; Girard PM; Lacombe K
Liver Int; 2015 Mar; 35(3):795-804. PubMed ID: 24606220
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients.
Maylin S; Boyd A; Lavocat F; Gozlan J; Lascoux-Combe C; Miailhes P; Lassel L; Delaugerre C; Girard PM; Zoulim F; Lacombe K
AIDS; 2012 May; 26(8):939-49. PubMed ID: 22333748
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from Sub-Saharan Africa.
Boyd A; Maylin S; Moh R; Mahjoub N; Gabillard D; Eholié SP; Danel C; Anglaret X; Zoulim F; Girard PM; Delaugerre C; Lacombefor K;
J Gastroenterol Hepatol; 2016 Mar; 31(3):634-44. PubMed ID: 26313291
[TBL] [Abstract][Full Text] [Related]
4. Intensification with pegylated interferon during treatment with tenofovir in HIV-hepatitis B virus co-infected patients.
Boyd A; Piroth L; Maylin S; Maynard-Muet M; Lebossé F; Bouix C; Lascoux-Combe C; Mahjoub N; Girard PM; Delaugerre C; Carrat F; Lacombe K; Miailhes P
J Viral Hepat; 2016 Dec; 23(12):1017-1026. PubMed ID: 27486094
[TBL] [Abstract][Full Text] [Related]
5. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir.
Lee JM; Ahn SH; Kim HS; Park H; Chang HY; Kim DY; Hwang SG; Rim KS; Chon CY; Han KH; Park JY
Hepatology; 2011 May; 53(5):1486-93. PubMed ID: 21520167
[TBL] [Abstract][Full Text] [Related]
6. Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.
Miailhes P; Maynard-Muet M; Lebossé F; Carrat F; Bouix C; Lascoux-Combe C; Sogni P; Rey D; Barthe Y; Pol S; Cacoub P; Zoulim F; Piroth L
J Hepatol; 2014 Oct; 61(4):761-9. PubMed ID: 24882048
[TBL] [Abstract][Full Text] [Related]
7. Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.
Kosi L; Reiberger T; Payer BA; Grabmeier-Pfistershammer K; Strassl R; Rieger A; Peck-Radosavljevic M
J Viral Hepat; 2012 Nov; 19(11):801-10. PubMed ID: 23043387
[TBL] [Abstract][Full Text] [Related]
8. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ
Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735
[TBL] [Abstract][Full Text] [Related]
9. Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications.
Boyd A; Gozlan J; Maylin S; Delaugerre C; Peytavin G; Girard PM; Zoulim F; Lacombe K
Hepatology; 2014 Aug; 60(2):497-507. PubMed ID: 24752996
[TBL] [Abstract][Full Text] [Related]
10. Elevated pre-treatment IL-18 level is associated with HBeAg seroconversion in HIV-HBV coinfection.
Li Y; Xie J; Wang H; Han Y; Wang N; Thio CL; Li T
Antivir Ther; 2017; 22(6):523-527. PubMed ID: 28195558
[TBL] [Abstract][Full Text] [Related]
11. Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.
Boglione L; D'Avolio A; Cariti G; Gregori G; Burdino E; Baietto L; Cusato J; Ghisetti V; De Rosa FG; Di Perri G
Liver Int; 2013 Apr; 33(4):580-5. PubMed ID: 23311449
[TBL] [Abstract][Full Text] [Related]
12. Rates and determinants of hepatitis B 'e' antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus.
Boyd A; Gozlan J; Miailhes P; Lascoux-Combe C; Cam MS; Rougier H; Zoulim F; Girard PM; Lacombe K
AIDS; 2015 Sep; 29(15):1963-73. PubMed ID: 26153669
[TBL] [Abstract][Full Text] [Related]
13. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E
Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224
[TBL] [Abstract][Full Text] [Related]
14. Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals.
Matthews GV; Ali RJ; Avihingsanon A; Amin J; Hammond R; Bowden S; Lewin SR; Sasadeusz J; Littlejohn M; Locarnini SL; Ruxrungtham K; Dore GJ
PLoS One; 2013; 8(4):e61297. PubMed ID: 23593455
[TBL] [Abstract][Full Text] [Related]
15. Relevance of hepatitis B surface antigen levels in patients with chronic hepatitis B during 5 year of tenofovir treatment.
Singh AK; Sharma MK; Hissar SS; Gupta E; Sarin SK
J Viral Hepat; 2014 Jun; 21(6):439-46. PubMed ID: 24750522
[TBL] [Abstract][Full Text] [Related]
16. Quantitative hepatitis B surface antigen titres in Chinese chronic hepatitis B patients over 4 years of entecavir treatment.
Chen EQ; Wang TT; Bai L; Tao CM; Liang T; Liu C; Liao J; Tang H
Antivir Ther; 2013; 18(8):955-65. PubMed ID: 23639885
[TBL] [Abstract][Full Text] [Related]
17. Quantification of hepatitis B e antigen between Elecsys HBeAg and Architect HBeAg assays among patients infected with hepatitis B virus.
Maylin S; Boyd A; Martinot-Peignoux M; Delaugerre C; Bagnard G; Lapalus M; Zoulim F; Lavocat F; Marcellin P; Simon F; Girard PM; Lacombe K
J Clin Virol; 2013 Apr; 56(4):306-11. PubMed ID: 23369885
[TBL] [Abstract][Full Text] [Related]
18. HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients.
Wong D; Littlejohn M; Yuen L; Jackson K; Mason H; Bayliss J; Rosenberg G; Gaggar A; Kitrinos K; Subramanian M; Marcellin P; Buti M; Janssen HLA; Gane E; Locarnini S; Thompson A; Revill PA
Aliment Pharmacol Ther; 2018 Jan; 47(1):114-122. PubMed ID: 29023803
[TBL] [Abstract][Full Text] [Related]
19. Outcomes in HIV/HBV-Coinfected Patients in the Tenofovir Era Are Greatly Affected by Immune Suppression.
Huang AJ; Núñez M
J Int Assoc Provid AIDS Care; 2015; 14(4):360-8. PubMed ID: 25999329
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV.
Zoutendijk R; Zaaijer HL; de Vries-Sluijs TE; Reijnders JG; Mulder JW; Kroon FP; Richter C; van der Eijk AA; Sonneveld MJ; Hansen BE; de Man RA; van der Ende ME; Janssen HL
J Infect Dis; 2012 Sep; 206(6):974-80. PubMed ID: 22782950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
